{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:09:08Z","timestamp":1780549748902,"version":"3.54.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder caused by mutations in the NF1 gene, including exon deletions, which are associated with various phenotypes and plexiform neurofibromas. Plexiform neurofibromas are clinically observed in up to 30% (and up to 50% on MRI) of NF1 patients and may involve both external and internal tissues, with a risk of malignant transformation to malignant peripheral nerve sheath tumors (MPNST). This report presents a rare case of a large plexiform neurofibroma in an adolescent male with NF1, involving the hepatic hilum and surrounding hepatic vessels. The patient, born in 2002, presented with multiple caf\u00e9-au-lait macules, cutaneous neurofibromas, axillary freckling, and headaches. Imaging studies, including 3-Tesla MRI and multislice CT, revealed a multinodular lesion extending along the hepatic vessels, around the gallbladder, the celiac trunk, and adjacent pancreatic and duodenal structures. Genetic testing confirmed a large deletion of an exon in the\n                    <jats:italic>NF1<\/jats:italic>\n                    gene. Due to the lesion\u2019s inoperable location and risk of vascular and biliary compression, targeted therapy with the MEK inhibitor selumetinib was indicated. The patient is currently awaiting provision of the medication. This case underscores the importance of careful monitoring and early initiation of targeted therapy in NF1 patients with extensive plexiform neurofibromas, particularly those caused by large\n                    <jats:italic>NF1<\/jats:italic>\n                    gene deletions, which result in complete loss of neurofibromin and extensive infiltrative benign tumor growth.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1771419","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:57:42Z","timestamp":1780549062000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Clinical case of a giant plexiform neurofibroma of the liver in a patient with deletion of exon 1 of the NF1 gene"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhannat","family":"Idrissova","sequence":"first","affiliation":[{"name":"Competence Center for Neurological Orphan Diseases, University Clinic Aksai, Asfendiyarov Kazakh National Medial University","place":["Almaty, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Orazgaliyeva","sequence":"additional","affiliation":[{"name":"Center for Molecular Genetic research in Kazakh Institute of Oncology and Radiology","place":["Almaty, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Kovaleva","sequence":"additional","affiliation":[{"name":"Genomic Laboratory, Asfendiyarov Kazakh National Medial University","place":["Almaty, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanel","family":"Seilkhanova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Asfendiyarov Kazakh National Medical University","place":["Almaty, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Rakhimbekova","sequence":"additional","affiliation":[{"name":"Competence Center for Neurological Orphan Diseases, University Clinic Aksai, Asfendiyarov Kazakh National Medial University","place":["Almaty, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Zhaksybek","sequence":"additional","affiliation":[{"name":"Competence Center for Neurological Orphan Diseases, University Clinic Aksai, Asfendiyarov Kazakh National Medial University","place":["Almaty, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariga","family":"Myrzamuratova","sequence":"additional","affiliation":[{"name":"Competence Center for Neurological Orphan Diseases, University Clinic Aksai, Asfendiyarov Kazakh National Medial University","place":["Almaty, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041217","article-title":"Neurofibromatosis type 1: pediatric aspects and review of genotype-phenotype correlations","volume":"15","author":"Peduto","year":"2023","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2020.0354","article-title":"The neurofibromatoses","volume":"117","author":"Said Farschtschi","year":"2020","journal-title":"Deutsches \u00c4rzteblatt Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5152\/balkanmedj.2021.21006","article-title":"Clinical characteristics and variant spectrum of neurofibromatosis type 1 in 27 Turkish families","volume":"38","author":"Sharifi","year":"2021","journal-title":"Balkan Med J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GIM.0b013e3181bf15e3","article-title":"Clinical and genetic aspects of neurofibromatosis 1","volume":"12","author":"Jett","year":"2010","journal-title":"Genet Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.08.051","article-title":"Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1","volume":"160","author":"Prada","year":"2012","journal-title":"J Pediatr"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008092","article-title":"Imaging biomarkers for Malignant peripheral nerve sheath tumors in neurofibromatosis type 1","volume":"93","author":"Ahlawat","year":"2019","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.jid.2024.01.028","article-title":"Whole-body positron emission tomography with 18F-fluorodeoxyglucose\/magnetic resonance imaging as a screening tool for the detection of Malignant transformation in individuals with neurofibromatosis type 1","volume":"144","author":"Fertitta","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pbc.24212","article-title":"18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or Malignant peripheral nerve sheath tumors (MPNST)","volume":"60","author":"Meany","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1372-22","article-title":"Neurofibromatosis type 1 with a giant diffuse plexiform neurofibroma invading the liver","volume":"62","author":"Yokogawa","year":"2023","journal-title":"Intern Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12935-020-01570-8","article-title":"Advancement in research and therapy of NF1 mutant Malignant tumors","volume":"20","author":"Tao","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00986-9","article-title":"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study","volume":"405","author":"Chen","year":"2025","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1-associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1771419\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:57:49Z","timestamp":1780549069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1771419\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":15,"alternative-id":["10.3389\/fonc.2026.1771419"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1771419","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1771419"}}